EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In the era of monoclonal antibodies targeting the calcitonin gene-related peptide pathway, is it still necessary to stop taking excessive pain medication?

Renata Gomes Londero iD

Arquivos de Neuro-Psiquiatria · 01.09.2025 · 83 (09) · 001-002

DOI: 10.1055/s-0045-1809333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arquivos de Neuro-Psiquiatria, erschienen am 01.09.2025. Verfasst von Renata Gomes Londero. Beteiligte Einrichtung: Hospital de Clínicas de Porto Alegre, Serviço de Neurologia, Clínica de Cefaleia, Porto Alegre RS, Brazil. Hauptthemen laut MEDLINE: Analgesics, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Headache Disorders, Secondary. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medication-overuse headache (MOH) was first described in 1951 with ergotamine overuse. Since then, much has been studied about its risk factors, pathophysiology, prevention, and treatment. Despite this, many people still suffer from this condition. Even for those who reach medical care, the path to maintaining significant improvement is neither short nor easy. Here, we propose the ubiquitous individualization of headache treatment. The more we study the condition, the more it becomes evident that different groups of patients benefit from different approaches: starting prophylactic medication immediately or postponing it, providing a bridge treatment or not, and advising patients to either stop medication overuse immediately or reduce it gradually.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnalgesicsAntibodies, MonoclonalCalcitonin Gene-Related PeptideHeadache Disorders, SecondaryHumans

Substanzen

AnalgesicsAntibodies, MonoclonalCalcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • Hospital de Clínicas de Porto Alegre, Serviço de Neurologia, Clínica de Cefaleia, Porto Alegre RS, Brazil.

ORCID-Profile: Renata Gomes Londero

Zitieren

APA

Londero, R. G. (2025). In the era of monoclonal antibodies targeting the calcitonin gene-related peptide pathway, is it still necessary to stop taking excessive pain medication?. Arquivos de Neuro-Psiquiatria, 83(09), 001-002. https://doi.org/10.1055/s-0045-1809333

Vancouver

Londero RG. In the era of monoclonal antibodies targeting the calcitonin gene-related peptide pathway, is it still necessary to stop taking excessive pain medication?. Arquivos de Neuro-Psiquiatria. 2025;83(09):001-002. doi:10.1055/s-0045-1809333

BibTeX
@article{Londero2025,
  author = {Londero, Renata Gomes},
  title = {In the era of monoclonal antibodies targeting the calcitonin gene-related peptide pathway, is it still necessary to stop taking excessive pain medication?},
  journal = {Arquivos de Neuro-Psiquiatria},
  year = {2025},
  volume = {83},
  number = {09},
  pages = {001--002},
  doi = {10.1055/s-0045-1809333}
}
Kostenlos starten →